Search Results
DESTINY-Gastric02: T-Dxd as a second-line treatment for HER2-positive gastric cancer
DESTINY-Gastric02: 2L T-DXd in HER2+ gastric cancers
Updated analysis of DESTINY-Gastric02: T-DXd in HER2+ GEJ cancer who progressed with trastuzumab
Updates from DESTINY-Gastric 01
Choosing between tucatinib and T-DXd in HER2+ breast cancer
Advances in HER2-targeted therapies for gastric cancer
Dr. Mehta on the Current Treatment Paradigm in HER2-Positive Gastric Cancer
HER2-Positive Gastrointestinal Cancers: New Evidence and Practical Guidance With Targeted Agents
ASCO: Promising Results for Trastuzumab Deruxtecan for HER2+ Gastric Cancer
Practice-Changing Updates in the Second-Line Treatment of Gastric/GEJ Cancer (2 of 2)
Trastuzumab Deruxtecan for Patients w/ HER2-Positive Advanced Gastric or GE Junction Adenocarcinoma
38 Second Line & Later Therapy for HER2+
